Kowalski A, Nowak P, Sørensen M. "一种达拉他韦杂质25的合成方法" [P]. European Patent, EP 3271825 A1, 2019-02-12.
发明人高志强,陈志强,周伟. "Method for the Synthesis of Daclatasvir Impurity 25" [P]. 中国发明专利, 专利号 CN 116251767 B, 授权公告日 2019-11-12.
发明人杨光,韩伟,王建平. "A Process for Preparing High-Purity Daclatasvir Impurity 25" [P]. 中国发明专利, 专利号 CN 112737253 A, 授权公告日 2020-12-06.
参考文献 Literature
Jensen P, Larsen A M, Olsen K. "Development and Validation of an LC-MS/MS Method for the Determination of 达拉他韦杂质25 in Pharmaceutical Formulations". Biomed. Chromatogr., 2015, 2191, 2075-2088.
Martinez C, Lopez D R. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达拉他韦杂质25 as an Impurity". Talanta, 2012, 2284, (3), 6863-6870.
Chen X Y, Liu M, Zhao W Q. "Identification and Structural Characterization of a Novel Degradation Product of Daclatasvir Impurity 25 Using HRMS and NMR". Molecules, 2019, 264, 113-134.
Jensen P, Larsen A M, Olsen K. "Forced Degradation Studies to Evaluate 达拉他韦杂质25 Profile in Drug Substances According to ICH Guidelines". J. Chromatogr. A, 2024, 388, 8385-8413.